array(40) {
  [0]=>
  string(4) "1701"
  ["article_id"]=>
  string(4) "1701"
  [1]=>
  string(63) "Health Care Spending Per Person Increased to $5,641 in 2017"
  ["article_title"]=>
  string(63) "Health Care Spending Per Person Increased to $5,641 in 2017"
  [2]=>
  string(150) "TUESDAY, Feb. 12, 2019 -- In 2017, health care spending per person reached $5,641, according to the Health Care Cost Institute (HCCI) annual Health Ca"
  ["short_description"]=>
  string(150) "TUESDAY, Feb. 12, 2019 -- In 2017, health care spending per person reached $5,641, according to the Health Care Cost Institute (HCCI) annual Health Ca"
  [3]=>
  string(252) "TUESDAY, Feb. 12, 2019 -- In 2017, health care spending per person reached $5,641, according to the Health Care Cost Institute (HCCI) annual Health Care Cost and Utilization Report.&#nlResearchers from the HCCI examined medical and prescription drug..."
  ["description"]=>
  string(252) "TUESDAY, Feb. 12, 2019 -- In 2017, health care spending per person reached $5,641, according to the Health Care Cost Institute (HCCI) annual Health Care Cost and Utilization Report.&#nlResearchers from the HCCI examined medical and prescription drug..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(208) "https://www.drugs.com/news/health-care-spending-per-person-increased-36-5-641-2017-80410.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Care+Spending+Per+Person+Increased+to+%26%2336%3B5%2C641+in+2017"
  ["blog_url"]=>
  string(208) "https://www.drugs.com/news/health-care-spending-per-person-increased-36-5-641-2017-80410.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Care+Spending+Per+Person+Increased+to+%26%2336%3B5%2C641+in+2017"
  [15]=>
  string(19) "2019-02-13 03:00:22"
  ["add_date"]=>
  string(19) "2019-02-13 03:00:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1702"
  ["article_id"]=>
  string(4) "1702"
  [1]=>
  string(58) "Larger Physician Bonus May Improve Care in Chronic Disease"
  ["article_title"]=>
  string(58) "Larger Physician Bonus May Improve Care in Chronic Disease"
  [2]=>
  string(150) "TUESDAY, Feb. 12, 2019 -- Increased bonus size for physicians caring for patients with chronic disease is associated with improvements in care quality"
  ["short_description"]=>
  string(150) "TUESDAY, Feb. 12, 2019 -- Increased bonus size for physicians caring for patients with chronic disease is associated with improvements in care quality"
  [3]=>
  string(254) "TUESDAY, Feb. 12, 2019 -- Increased bonus size for physicians caring for patients with chronic disease is associated with improvements in care quality, according to a study published online Feb. 8 in JAMA Network Open.&#nlAmol S. Navathe, M.D., Ph.D.,..."
  ["description"]=>
  string(254) "TUESDAY, Feb. 12, 2019 -- Increased bonus size for physicians caring for patients with chronic disease is associated with improvements in care quality, according to a study published online Feb. 8 in JAMA Network Open.&#nlAmol S. Navathe, M.D., Ph.D.,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(187) "https://www.drugs.com/news/larger-physician-bonus-may-improve-care-chronic-80407.html?utm_source=ddc&utm_medium=rss&utm_campaign=Larger+Physician+Bonus+May+Improve+Care+in+Chronic+Disease"
  ["blog_url"]=>
  string(187) "https://www.drugs.com/news/larger-physician-bonus-may-improve-care-chronic-80407.html?utm_source=ddc&utm_medium=rss&utm_campaign=Larger+Physician+Bonus+May+Improve+Care+in+Chronic+Disease"
  [15]=>
  string(19) "2019-02-13 03:00:06"
  ["add_date"]=>
  string(19) "2019-02-13 03:00:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1728"
  ["article_id"]=>
  string(4) "1728"
  [1]=>
  string(59) "RPS Fellow Raj Aggarwal rises in honorary Royal Navy ranks "
  ["article_title"]=>
  string(59) "RPS Fellow Raj Aggarwal rises in honorary Royal Navy ranks "
  [2]=>
  string(150) "Royal Pharmaceutical Society Fellow Raj Aggarwal has been promoted to the rank of honorary commander in the Royal Navy. He is affiliated to HMS Dragon"
  ["short_description"]=>
  string(150) "Royal Pharmaceutical Society Fellow Raj Aggarwal has been promoted to the rank of honorary commander in the Royal Navy. He is affiliated to HMS Dragon"
  [3]=>
  string(169) "Royal Pharmaceutical Society Fellow Raj Aggarwal has been promoted to the rank of honorary commander in the Royal Navy. He is affiliated to HMS Dragon, based in Cardiff."
  ["description"]=>
  string(169) "Royal Pharmaceutical Society Fellow Raj Aggarwal has been promoted to the rank of honorary commander in the Royal Navy. He is affiliated to HMS Dragon, based in Cardiff."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(123) "https://www.pharmaceutical-journal.com/your-rps/rps-fellow-raj-aggarwal-rises-in-honorary-royal-navy-ranks/20206150.article"
  ["blog_url"]=>
  string(123) "https://www.pharmaceutical-journal.com/your-rps/rps-fellow-raj-aggarwal-rises-in-honorary-royal-navy-ranks/20206150.article"
  [15]=>
  string(19) "2019-02-13 00:44:00"
  ["add_date"]=>
  string(19) "2019-02-13 00:44:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:36"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1729"
  ["article_id"]=>
  string(4) "1729"
  [1]=>
  string(84) "IT provider to adjust system after 'ghost branded generics' cost NHS £12m"
  ["article_title"]=>
  string(84) "IT provider to adjust system after 'ghost branded generics' cost NHS £12m"
  [2]=>
  string(158) "A GP IT service provider has said it will change its systems after it was revealed that GPs were able to prescribe “ghost branded generics”, costi"
  ["short_description"]=>
  string(158) "A GP IT service provider has said it will change its systems after it was revealed that GPs were able to prescribe “ghost branded generics”, costi"
  [3]=>
  string(236) "A GP IT service provider has said it will change its systems after it was revealed that GPs were able to prescribe “ghost branded generics”, costing the NHS an extra £11.6m per year in reimbursement to community pharmacy."
  ["description"]=>
  string(236) "A GP IT service provider has said it will change its systems after it was revealed that GPs were able to prescribe “ghost branded generics”, costing the NHS an extra £11.6m per year in reimbursement to community pharmacy."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(149) "https://www.pharmaceutical-journal.com/news-and-analysis/news/it-provider-to-adjust-system-after-ghost-branded-generics-cost-nhs-12m/20206142.article"
  ["blog_url"]=>
  string(149) "https://www.pharmaceutical-journal.com/news-and-analysis/news/it-provider-to-adjust-system-after-ghost-branded-generics-cost-nhs-12m/20206142.article"
  [15]=>
  string(19) "2019-02-13 00:43:00"
  ["add_date"]=>
  string(19) "2019-02-13 00:43:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:36"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1688"
  ["article_id"]=>
  string(4) "1688"
  [1]=>
  string(52) "More U.S. Men Holding Off on Prostate Cancer Surgery"
  ["article_title"]=>
  string(52) "More U.S. Men Holding Off on Prostate Cancer Surgery"
  [2]=>
  string(150) "TUESDAY, Feb. 12, 2019 -- Many more American men are now saying no to surgery for low-risk prostate cancer, and choosing to monitor the disease instea"
  ["short_description"]=>
  string(150) "TUESDAY, Feb. 12, 2019 -- Many more American men are now saying no to surgery for low-risk prostate cancer, and choosing to monitor the disease instea"
  [3]=>
  string(250) "TUESDAY, Feb. 12, 2019 -- Many more American men are now saying no to surgery for low-risk prostate cancer, and choosing to monitor the disease instead, a new study finds.&#nlOver just five years, researchers found, the number of men who opted for..."
  ["description"]=>
  string(250) "TUESDAY, Feb. 12, 2019 -- Many more American men are now saying no to surgery for low-risk prostate cancer, and choosing to monitor the disease instead, a new study finds.&#nlOver just five years, researchers found, the number of men who opted for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(182) "https://www.drugs.com/news/more-u-s-men-holding-off-prostate-cancer-surgery-80391.html?utm_source=ddc&utm_medium=rss&utm_campaign=More+U.S.+Men+Holding+Off+on+Prostate+Cancer+Surgery"
  ["blog_url"]=>
  string(182) "https://www.drugs.com/news/more-u-s-men-holding-off-prostate-cancer-surgery-80391.html?utm_source=ddc&utm_medium=rss&utm_campaign=More+U.S.+Men+Holding+Off+on+Prostate+Cancer+Surgery"
  [15]=>
  string(19) "2019-02-12 20:02:13"
  ["add_date"]=>
  string(19) "2019-02-12 20:02:13"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1689"
  ["article_id"]=>
  string(4) "1689"
  [1]=>
  string(51) "AHA News: Are There Health Benefits From Chocolate?"
  ["article_title"]=>
  string(51) "AHA News: Are There Health Benefits From Chocolate?"
  [2]=>
  string(158) "TUESDAY, Feb. 12, 2019 (American Heart Association News) -- Every year, Americans spend $22 billion on chocolate, and it's a safe bet that Valentine's"
  ["short_description"]=>
  string(158) "TUESDAY, Feb. 12, 2019 (American Heart Association News) -- Every year, Americans spend $22 billion on chocolate, and it's a safe bet that Valentine's"
  [3]=>
  string(256) "TUESDAY, Feb. 12, 2019 (American Heart Association News) -- Every year, Americans spend $22 billion on chocolate, and it's a safe bet that Valentine's Day accounts for a decent percentage of that total. While a heart-shaped box of chocolates may..."
  ["description"]=>
  string(256) "TUESDAY, Feb. 12, 2019 (American Heart Association News) -- Every year, Americans spend $22 billion on chocolate, and it's a safe bet that Valentine's Day accounts for a decent percentage of that total. While a heart-shaped box of chocolates may..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(177) "https://www.drugs.com/news/aha-news-there-health-benefits-chocolate-80393.html?utm_source=ddc&utm_medium=rss&utm_campaign=AHA+News%3A+Are+There+Health+Benefits+From+Chocolate%3F"
  ["blog_url"]=>
  string(177) "https://www.drugs.com/news/aha-news-there-health-benefits-chocolate-80393.html?utm_source=ddc&utm_medium=rss&utm_campaign=AHA+News%3A+Are+There+Health+Benefits+From+Chocolate%3F"
  [15]=>
  string(19) "2019-02-12 20:02:04"
  ["add_date"]=>
  string(19) "2019-02-12 20:02:04"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1711"
  ["article_id"]=>
  string(4) "1711"
  [1]=>
  string(126) "FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression"
  ["article_title"]=>
  string(126) "FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression"
  [2]=>
  string(150) "TITUSVILLE, N.J., February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug "
  ["short_description"]=>
  string(150) "TITUSVILLE, N.J., February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug "
  [3]=>
  string(242) "TITUSVILLE, N.J., February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk..."
  ["description"]=>
  string(242) "TITUSVILLE, N.J., February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(220) "https://www.drugs.com/nda/spravato_190212.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Advisory+Committee+Recommends+Approval+of+Spravato+%28esketamine%29+Nasal+Spray+for+Adults+with+Treatment-Resistant+Depression"
  ["blog_url"]=>
  string(220) "https://www.drugs.com/nda/spravato_190212.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Advisory+Committee+Recommends+Approval+of+Spravato+%28esketamine%29+Nasal+Spray+for+Adults+with+Treatment-Resistant+Depression"
  [15]=>
  string(19) "2019-02-12 13:02:54"
  ["add_date"]=>
  string(19) "2019-02-12 13:02:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1705"
  ["article_id"]=>
  string(4) "1705"
  [1]=>
  string(56) "FDA Approves Darzalex (daratumumab) Split-Dosing Regimen"
  ["article_title"]=>
  string(56) "FDA Approves Darzalex (daratumumab) Split-Dosing Regimen"
  [2]=>
  string(150) "Horsham, PA, February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Admin"
  ["short_description"]=>
  string(150) "Horsham, PA, February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Admin"
  [3]=>
  string(247) "Horsham, PA, February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex® (daratumumab), providing..."
  ["description"]=>
  string(247) "Horsham, PA, February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex® (daratumumab), providing..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(199) "https://www.drugs.com/newdrugs/fda-approves-darzalex-daratumumab-split-dosing-regimen-4915.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Darzalex+%28daratumumab%29+Split-Dosing+Regimen"
  ["blog_url"]=>
  string(199) "https://www.drugs.com/newdrugs/fda-approves-darzalex-daratumumab-split-dosing-regimen-4915.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Darzalex+%28daratumumab%29+Split-Dosing+Regimen"
  [15]=>
  string(19) "2019-02-12 12:02:50"
  ["add_date"]=>
  string(19) "2019-02-12 12:02:50"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1762"
  ["article_id"]=>
  string(4) "1762"
  [1]=>
  string(63) "UK Pharma Group Worries About Post-Brexit Supply Chain Security"
  ["article_title"]=>
  string(63) "UK Pharma Group Worries About Post-Brexit Supply Chain Security"
  [2]=>
  string(158) "&#nl        A new EU safety net for snaring illicit drugs went into effect on Feb. 9 — but the UK may not be under its protection for very long, accord"
  ["short_description"]=>
  string(158) "&#nl        A new EU safety net for snaring illicit drugs went into effect on Feb. 9 — but the UK may not be under its protection for very long, accord"
  [3]=>
  string(237) "&#nl        A new EU safety net for snaring illicit drugs went into effect on Feb. 9 — but the UK may not be under its protection for very long, according to the Association of the British Pharmaceutical Industry (ABPI).&#nl      "
  ["description"]=>
  string(237) "&#nl        A new EU safety net for snaring illicit drugs went into effect on Feb. 9 — but the UK may not be under its protection for very long, according to the Association of the British Pharmaceutical Industry (ABPI).&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(103) "https://www.fdanews.com/articles/190200-uk-pharma-group-worries-about-post-brexit-supply-chain-security"
  ["blog_url"]=>
  string(103) "https://www.fdanews.com/articles/190200-uk-pharma-group-worries-about-post-brexit-supply-chain-security"
  [15]=>
  string(19) "2019-02-12 06:45:15"
  ["add_date"]=>
  string(19) "2019-02-12 06:45:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1763"
  ["article_id"]=>
  string(4) "1763"
  [1]=>
  string(73) "Pfizer Questions Drug ‘Total Content’ in Biosimilar Guidance"
  ["article_title"]=>
  string(73) "Pfizer Questions Drug ‘Total Content’ in Biosimilar Guidance"
  [2]=>
  string(161) "&#nl        Pfizer asked the FDA to clarify the term “total content” in its draft guidance for biosimilar development, for demonstrating that a drug "
  ["short_description"]=>
  string(161) "&#nl        Pfizer asked the FDA to clarify the term “total content” in its draft guidance for biosimilar development, for demonstrating that a drug "
  [3]=>
  string(218) "&#nl        Pfizer asked the FDA to clarify the term “total content” in its draft guidance for biosimilar development, for demonstrating that a drug and a reference product have the same strength.&#nl      "
  ["description"]=>
  string(218) "&#nl        Pfizer asked the FDA to clarify the term “total content” in its draft guidance for biosimilar development, for demonstrating that a drug and a reference product have the same strength.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(98) "https://www.fdanews.com/articles/190198-pfizer-questions-drug-total-content-in-biosimilar-guidance"
  ["blog_url"]=>
  string(98) "https://www.fdanews.com/articles/190198-pfizer-questions-drug-total-content-in-biosimilar-guidance"
  [15]=>
  string(19) "2019-02-12 06:43:19"
  ["add_date"]=>
  string(19) "2019-02-12 06:43:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1742"
  ["article_id"]=>
  string(4) "1742"
  [1]=>
  string(103) "FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis"
  ["article_title"]=>
  string(103) "FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis"
  [2]=>
  string(150) "SAN DIEGO – February 11, 2019 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, anno"
  ["short_description"]=>
  string(150) "SAN DIEGO – February 11, 2019 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, anno"
  [3]=>
  string(250) "SAN DIEGO – February 11, 2019 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development..."
  ["description"]=>
  string(250) "SAN DIEGO – February 11, 2019 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(270) "https://www.drugs.com/clinical_trials/fda-grants-orphan-designation-amplyx-pharmaceuticals-apx001-cryptococcosis-18075.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Grants+Orphan+Drug+Designation+to+Amplyx+Pharmaceuticals+for+APX001+for+Treatment+of+Cryptococcosis"
  ["blog_url"]=>
  string(270) "https://www.drugs.com/clinical_trials/fda-grants-orphan-designation-amplyx-pharmaceuticals-apx001-cryptococcosis-18075.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Grants+Orphan+Drug+Designation+to+Amplyx+Pharmaceuticals+for+APX001+for+Treatment+of+Cryptococcosis"
  [15]=>
  string(19) "2019-02-12 06:02:39"
  ["add_date"]=>
  string(19) "2019-02-12 06:02:39"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1743"
  ["article_id"]=>
  string(4) "1743"
  [1]=>
  string(153) "Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria"
  ["article_title"]=>
  string(153) "Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria"
  [2]=>
  string(150) "WALTHAM Mass., and CRESTWOOD, Ky., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical co"
  ["short_description"]=>
  string(150) "WALTHAM Mass., and CRESTWOOD, Ky., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical co"
  [3]=>
  string(245) "WALTHAM Mass., and CRESTWOOD, Ky., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the..."
  ["description"]=>
  string(245) "WALTHAM Mass., and CRESTWOOD, Ky., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-fda-patients-paroxysmal-nocturnal-18074.html?utm_source=ddc&utm_medium=rss&utm_campaign=Apellis+Pharmaceuticals%E2%80%99+APL-2+Receives+Fast+Track+Designation+from+the+FDA+for+the+Treatment+of+Patient"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-fda-patients-paroxysmal-nocturnal-18074.html?utm_source=ddc&utm_medium=rss&utm_campaign=Apellis+Pharmaceuticals%E2%80%99+APL-2+Receives+Fast+Track+Designation+from+the+FDA+for+the+Treatment+of+Patient"
  [15]=>
  string(19) "2019-02-12 06:02:34"
  ["add_date"]=>
  string(19) "2019-02-12 06:02:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}